Facial erythema and telangiectasia with synalar cream
Tirlapur, V.G.; Rice-Oxley, J.M.
British Journal of Clinical Practice 35(7-8): 275-276
1981
ISSN/ISBN: 0007-0947 PMID: 7317261 Document Number: 172298
Document emailed within 1 workday
Related Documents
Garcia, C.; Birch, M. 2018: Oxymetazoline Hydrochloride 1% Cream (Rhofade) for Persistent Facial Erythema Associated with Rosacea American Family Physician 97(12): 808-810Tanghetti, E.A.; Dover, J.S.; Goldberg, D.J.; Dhawan, S.S.; Luo, L.; Berk, D.R.; Ahluwalia, G.; Alvandi, N. 2018: Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the first day of Treatment with Oxymetazoline Cream 1.0 Journal of Drugs in Dermatology: Jdd 17(6): 621-626
Stein-Gold, L.; Kircik, L.; Draelos, Z.D.; Werschler, P.; DuBois, J.; Lain, E.; Baumann, L.; Goldberg, D.; Kaufman, J.; Tanghetti, E.; Ahluwalia, G.; Alvandi, N.; Weng, E.; Berk, D. 2018: Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated with Rosacea: Pooled Analysis of the two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials Journal of Drugs in Dermatology: Jdd 17(11): 1201-1208
Baumann, L.; Goldberg, D.J.; Stein Gold, L.; Tanghetti, E.A.; Lain, E.; Kaufman, J.; Weng, E.; Berk, D.R.; Ahluwalia, G. 2018: Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated with Rosacea: Findings from the Second REVEAL Trial Journal of Drugs in Dermatology: Jdd 17(3): 290-298
Kircik, L.H.; DuBois, J.; Draelos, Z.D.; Werschler, P.; Grande, K.; Cook-Bolden, F.E.; Weng, E.; Berk, D.R.; Ahluwalia, G. 2018: Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated with Rosacea: Findings from the first REVEAL Trial Journal of Drugs in Dermatology: Jdd 17(1): 97-105
Shalita, A.; Miller, B.; Menter, A.; Abramovits, W.; Loven, K.; Kakita, L. 2005: Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study Journal of Drugs in Dermatology: Jdd 4(2): 153-158
Paukstadt, W. 2005: Always consider complications in facial erythema MMW Fortschritte der Medizin 147(41): 15-16
Lee, C.S.; Koo, J. 2009: The efficacy of three class i topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison Journal of Drugs in Dermatology: Jdd 8(8): 751-755
Mayoral, F.A.; Vega, J.M.; Stavisky, H.; McCormick, C.L.; Parneix-Spake, A. 2007: Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo Journal of Drugs in Dermatology: Jdd 6(5): 517-521
Raschka, C. 2013: Red swollen helix, facial erythema a week later. Borrelia lymphocytoma MMW Fortschritte der Medizin 155(16): 5; 49
Gao, L.; Gao, N.; Song, W.; Dang, E.; Yin, R.; Wang, L.; Wang, G. 2017: A Retrospective Study on Efficacy of Pulsed Dye Laser and Intense Pulsed Light for the Treatment of Facial Telangiectasia Journal of Drugs in Dermatology: Jdd 16(11): 1112-1116
Kircik, L.H.; Del Rosso, J.Q. 2012: The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream Journal of Drugs in Dermatology: Jdd 11(10): 1194-1198
Kueh, Y.K.; LaBrooy, S. 1985: Hereditary haemorrhagic telangiectasia: the use of H2 receptor antagonist in symptomatic gastric telangiectasia Annals of the Academy of Medicine Singapore 14(4): 682-685
Nielsen, J.C.; Arendt-Nielsen, L.; Bjerring, P.; Svensson, P. 1992: The analgesic effect of EMLA cream on facial skin. Quantitative evaluation using argon laser stimulation Acta Dermato-Venereologica 72(4): 281-284
Kircik, L.H. 2009: Tretinoin microsphere gel pump 0.04% versus tazarotene cream 0.05% in the treatment of mild-to-moderate facial acne vulgaris Journal of Drugs in Dermatology: Jdd 8(7): 650-654
Fuchs, K.O.; Solis, O.; Tapawan, R.; Paranjpe, J. 2003: The effects of an estrogen and glycolic acid cream on the facial skin of postmenopausal women: a randomized histologic study Cutis 71(6): 481-488
Tanghetti, E.; Dhawan, S.; Green, L.; Del Rosso, J.; Draelos, Z.; Leyden, J.; Shalita, A.; Glaser, D.A.; Grimes, P.; Webster, G.; Barnett, P.; Le Gall, N. 2010: Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris Journal of Drugs in Dermatology: Jdd 9(5): 549-558
Mazzetti, A.; Moro, L.; Gerloni, M.; Cartwright, M. 2019: A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects with Facial Acne Journal of Drugs in Dermatology: Jdd 18(6): 570
Becker, Y.; Tabor, E. 1989: Skin fibroblasts from patients with the genetic disorder hereditary hemorrhagic telangiectasia compared with ataxia-telangiectasia fibroblasts in their response to the radiomimetic drug neocarzinostatin Israel Journal of Medical Sciences 25(2): 81-86
Moore, A.; Kempers, S.; Murakawa, G.; Weiss, J.; Tauscher, A.; Swinyer, L.; Liu, H.; Leoni, M. 2014: Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study Journal of Drugs in Dermatology: Jdd 13(1): 56-61